Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger G Pertwee

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
Journal of Medicinal Chemistry|July 11, 2018
Identification of the First Synthetic Allosteric Modulator of the CB<sub>2</sub> Receptors and Evidence of Its Efficacy for Neuropathic Pain ReliefFrancesca Gado, Lorenzo Di Cesare Mannelli, Elena Lucarini, et al.
Frontiers in Pharmacology|November 17, 2022
Pharmacological evaluation of enantiomerically separated positive allosteric modulators of cannabinoid 1 receptor, GAT591 and GAT593Asher L Brandt, Sumanta Garai, Ayat Zagzoog, et al.
Bioorganic & Medicinal Chemistry|July 5, 2005
Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activitiesBrian F Thomas, Maria Elena Y Francisco, Herbert H Seltzman, et al.
Bioorganic & Medicinal Chemistry|July 29, 2014
Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonistAntonella Brizzi, Francesca Aiello, Pietro Marini, et al.
Frontiers in Chemistry|October 14, 2022
Design, synthesis and biological evaluation of novel orthosteric-allosteric ligands of the cannabinoid receptor type 2 (CB<sub>2</sub>R)Rebecca Ferrisi, Francesca Gado, Beatrice Polini, et al.
British Journal of Pharmacology|April 8, 2011
Δ8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptorsSándor Bátkai, Partha Mukhopadhyay, Bėla Horváth, et al.
Molecular Pharmacology|November 20, 2012
CB(1) receptor allosteric modulators display both agonist and signaling pathway specificityGemma L Baillie, James G Horswill, Sharon Anavi-Goffer, et al.
European Journal of Pharmacology|December 1, 2010
Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonistJenny L Wiley, Christopher S Breivogel, Anu Mahadevan, et al.
Molecules (Basel, Switzerland)|May 14, 2022
Synthesis and In Vitro Characterization of Selective Cannabinoid CB2 Receptor Agonists: Biological Evaluation against Neuroblastoma Cancer CellsFrancesca Gado, Rebecca Ferrisi, Sarah Di Somma, et al.
Behavioural Pharmacology|March 8, 2014
In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569Thomas F Gamage, Bogna M Ignatowska-Jankowska, Jenny L Wiley, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Journal of Medicinal Chemistry|July 11, 2018
Identification of the First Synthetic Allosteric Modulator of the CB<sub>2</sub> Receptors and Evidence of Its Efficacy for Neuropathic Pain ReliefFrancesca Gado, Lorenzo Di Cesare Mannelli, Elena Lucarini, et al.
Frontiers in Pharmacology|November 17, 2022
Pharmacological evaluation of enantiomerically separated positive allosteric modulators of cannabinoid 1 receptor, GAT591 and GAT593Asher L Brandt, Sumanta Garai, Ayat Zagzoog, et al.
Bioorganic & Medicinal Chemistry|July 5, 2005
Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activitiesBrian F Thomas, Maria Elena Y Francisco, Herbert H Seltzman, et al.
Bioorganic & Medicinal Chemistry|July 29, 2014
Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonistAntonella Brizzi, Francesca Aiello, Pietro Marini, et al.
Frontiers in Chemistry|October 14, 2022
Design, synthesis and biological evaluation of novel orthosteric-allosteric ligands of the cannabinoid receptor type 2 (CB<sub>2</sub>R)Rebecca Ferrisi, Francesca Gado, Beatrice Polini, et al.
British Journal of Pharmacology|April 8, 2011
Δ8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptorsSándor Bátkai, Partha Mukhopadhyay, Bėla Horváth, et al.
Molecular Pharmacology|November 20, 2012
CB(1) receptor allosteric modulators display both agonist and signaling pathway specificityGemma L Baillie, James G Horswill, Sharon Anavi-Goffer, et al.
European Journal of Pharmacology|December 1, 2010
Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonistJenny L Wiley, Christopher S Breivogel, Anu Mahadevan, et al.
Molecules (Basel, Switzerland)|May 14, 2022
Synthesis and In Vitro Characterization of Selective Cannabinoid CB2 Receptor Agonists: Biological Evaluation against Neuroblastoma Cancer CellsFrancesca Gado, Rebecca Ferrisi, Sarah Di Somma, et al.
Behavioural Pharmacology|March 8, 2014
In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569Thomas F Gamage, Bogna M Ignatowska-Jankowska, Jenny L Wiley, et al.
Pageof 11